Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 3Radiation Injuries 1Prostatic Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Hepatitis 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Chemical and Drug Induced Liver Injury 1Brain Injuries 1Bone Cysts 1Anatomic Stage IV Breast Cancer AJCC v8 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Cisplatin 8Etoposide 6Paclitaxel 5Ifosfamide 4Sunitinib 3Oxaliplatin 3Cyclophosphamide 3Brentuximab Vedotin 3tremelimumab 2pembrolizumab 2etoposide phosphate 2durvalumab 2Sirolimus 2Gemcitabine 2Everolimus 2Epirubicin 2Dexamethasone 2Carboplatin 2Bleomycin 2Bevacizumab 2tozuleristide 1rolapitant 1ribociclib 1pegfilgrastim 1pazopanib 1olaparib 1fosaprepitant 1fludarabine phosphate 1fludarabine 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Germ Cell and Embryonal × Steroids × Clear all
NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡